ObsEva SA (OBSV):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ObsEva SA (OBSV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9992
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ObsEva SA (ObsEva) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company’s product portfolio comprises pipeline products which is being developed to control preterm labor by reducing inflammation, decreasing uterine contractions and preventing cervical changes and membrane ruptures; for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. ObsEva is headquartered in Geneva, Switzerland.

ObsEva SA (OBSV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ObsEva SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ObsEva SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ObsEva SA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ObsEva Raises USD59 Million in Series B Financing Round 11
ObsEva Raises US$34.8 Million In Series A Financing 13
Licensing Agreements 14
ObsEva Enters into Licensing Agreement with Kissei Pharma 14
ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 15
ObsEva Enters Into Licensing Agreement With Merck Serono 16
Equity Offering 17
ObsEva Prices Public Offering of Shares for USD73.1 Million 17
ObsEva Raises USD60 Million in Private Placement of Shares and Warrants 19
ObsEva Completes IPO of Shares for USD96.75 million 21
ObsEva SA – Key Competitors 23
ObsEva SA – Key Employees 24
ObsEva SA – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 08, 2018: ObsEva reports third quarter 2018 financial results and provides business update 26
Aug 08, 2018: ObsEva reports second quarter 2018 financial results and provides business update 28
May 16, 2018: ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update 30
Mar 09, 2018: ObsEva Reports Fourth Quarter And Year-End 2017 Financial Results And Provides Business Update 31
Nov 14, 2017: ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update 33
Aug 15, 2017: ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update 34
May 18, 2017: ObsEva Reports First Quarter 2017 Financial Results and Business Update 35
Corporate Communications 36
Jul 25, 2018: ObsEva Expands Executive Team Hiring a Chief Commercial Officer 36
Jul 13, 2018: ObsEva to start trading on the SIX Swiss Exchange 37
Jun 01, 2018: ObsEva to Seek SIX Share Listing 38
Feb 01, 2018: Dr. Ernest Loumaye, CEO of ObsEva returns to work following a personal leave for medical reasons 39
Jan 17, 2017: ObsEva Expands Leadership Team and Board of Directors with Industry Veterans 40
Product News 41
06/29/2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting 41
03/17/2017: ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor 42
03/01/2018: ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting 43
Clinical Trials 44
Dec 05, 2017: ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor 44
Sep 11, 2017: ObsEva Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting 45
May 18, 2017: ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022 46
Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
ObsEva SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ObsEva SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ObsEva SA, Deals By Therapy Area, 2012 to YTD 2018 9
ObsEva SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ObsEva Raises USD59 Million in Series B Financing Round 11
ObsEva Raises US$34.8 Million In Series A Financing 13
ObsEva Enters into Licensing Agreement with Kissei Pharma 14
ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 15
ObsEva Enters Into Licensing Agreement With Merck Serono 16
ObsEva Prices Public Offering of Shares for USD73.1 Million 17
ObsEva Raises USD60 Million in Private Placement of Shares and Warrants 19
ObsEva Completes IPO of Shares for USD96.75 million 21
ObsEva SA, Key Competitors 23
ObsEva SA, Key Employees 24
ObsEva SA, Subsidiaries 25

List of Figures
ObsEva SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ObsEva SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ObsEva SA (OBSV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AVJennings Limited:企業の戦略・SWOT・財務情報
    AVJennings Limited - Strategy, SWOT and Corporate Finance Report Summary AVJennings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Piper Jaffray Companies:企業の戦略・SWOT・財務情報
    Piper Jaffray Companies - Strategy, SWOT and Corporate Finance Report Summary Piper Jaffray Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Scholastic Corp (SCHL)
    Scholastic Corp (SCHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • CoLucid Pharmaceuticals Inc (CLCD)-製薬・医療分野:企業M&A・提携分析
    Summary CoLucid Pharmaceuticals Inc (CoLucid) is a pharmaceutical company that conducts research and develops new therapies. CoLucid’s lead product candidate Lasmiditan (COL-144), is an oral tablet that penetrates the central nervous system and selectively targets 5-HT1F receptors expressed in the t …
  • Turner & Townsend Plc:企業の戦略的SWOT分析
    Turner & Townsend Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Adris grupa dd:企業の戦略・SWOT・財務分析
    Adris grupa dd - Strategy, SWOT and Corporate Finance Report Summary Adris grupa dd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Dr. Reddy’s Laboratories Limited:企業の戦略・SWOT・財務分析
    Dr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report Summary Dr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Walgreens Boots Alliance, Inc.:企業の戦略・SWOT・財務情報
    Walgreens Boots Alliance, Inc. - Strategy, SWOT and Corporate Finance Report Summary Walgreens Boots Alliance, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • National Grid Plc (NG):電力:M&Aディール及び事業提携情報
    Summary National Grid Plc (National Grid) is an energy utility. It transmits and distributes electricity and gas. The company owns and operates electricity and gas transmission and distribution networks; and is also the system operator for the Scottish networks. National Grid provides installation a …
  • Polpharma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Polpharma SA (Polpharma) undertakes the research, manufacture and marketing of generic drugs, prescription drugs and over the counter medications. It provides drugs in cardiology, gastroenterology and neurology areas. The company also manufactures over the counter (OTC) medications, dietary …
  • The Great-West Life Assurance Co:電力:M&Aディール及び事業提携情報
    Summary The Great-West Life Assurance Co (Great-West Life), a subsidiary of Great-West Lifeco Inc., focuses on life insurance, health insurance, retirement savings, investments, and reinsurance businesses. For individuals, it offers life insurance, disability insurance, critical illness insurance, h …
  • Impresa Pizzarotti & C. S.p.A.:企業の戦略・SWOT・財務情報
    Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • ViaCyte Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary ViaCyte Inc (ViaCyte), formerly Novocell Inc is a regenerative medicine company that centres on the development of cell replacement therapies for the treatment of diabetes. The company’s pipeline products portfolio includes VC-01, which is being developed as a therapy for T1D patients who ha …
  • NanoPass Technologies Ltd:医療機器:M&Aディール及び事業提携情報
    Summary NanoPass Technologies Ltd (NanoPass) is a medical device company that develops and commercializes intradermal delivery solutions for vaccines and drugs. The company's product include MicronJet600 needle, a single use microneedles based device for intradermal delivery. Its micronjet microneed …
  • GlobalSCAPE Inc (GSB):企業の財務・戦略的SWOT分析
    Summary GlobalSCAPE Inc (GlobalSCAPE) is a technology company that offers secure information exchange solutions. The company offers EFT platform products such as EFT enterprise, EFT express, public and private cloud, collaboration, automation and efficiency, protocols, security, compliance and analy …
  • Texwinca Holdings Limited:企業の戦略・SWOT・財務分析
    Texwinca Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Texwinca Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Neuralstem Inc (CUR):企業の財務・戦略的SWOT分析
    Summary Neuralstem Inc (Neuralstem) is a biopharmaceutical company that develops novel treatments for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer’s disease, traumatic brain injury, peri …
  • KineMed Inc-製薬・医療分野:企業M&A・提携分析
    Summary KineMed Inc (KineMed) is a biotechnology company that develops and commercializes proprietary biomarker platform technology. The company applies its proprietary biomarker platform technology to drug development, prescription, and non-prescription medical diagnostics and the pairing of drugs …
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196)-医療機器分野:企業M&A・提携分析
    Summary Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism …
  • PharmAust Ltd (PAA):企業の財務・戦略的SWOT分析
    Summary PharmAust Ltd (PAA) is a clinical-stage company that focuses on the development of targeted cancer therapeutics for the treatment of human and veterinary cancers. The company’s lead product candidate Monepantel is a small molecule that has been developed to treat parasite infections in food …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆